Idera Pharma enters into clinical development support agreement with Pillar Partners
Idera Pharma announced a clinical development support agreement with Pillar Partners Foundation. Under the agreement Pillar will provide direct funding to support three investigator initiated clinical trials to further strategically expand the clinical research of IMO-2125, Idera’s TLR 9 agonist. April 16, 2018